CO2021017845A2 - Proteínas multiespecíficas - Google Patents

Proteínas multiespecíficas

Info

Publication number
CO2021017845A2
CO2021017845A2 CONC2021/0017845A CO2021017845A CO2021017845A2 CO 2021017845 A2 CO2021017845 A2 CO 2021017845A2 CO 2021017845 A CO2021017845 A CO 2021017845A CO 2021017845 A2 CO2021017845 A2 CO 2021017845A2
Authority
CO
Colombia
Prior art keywords
multispecific proteins
multispecific
proteins
cancer
treatment
Prior art date
Application number
CONC2021/0017845A
Other languages
English (en)
Inventor
Christian Reichen
Alexander Link
Julia Hepp
Victor Levitsky
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of CO2021017845A2 publication Critical patent/CO2021017845A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cell Biology (AREA)

Abstract

Esta divulgación se refiere a proteínas recombinantes multiespecíficas útiles para el tratamiento de cáncer.
CONC2021/0017845A 2019-06-04 2021-12-27 Proteínas multiespecíficas CO2021017845A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962857037P 2019-06-04 2019-06-04
PCT/IB2020/055247 WO2020245746A1 (en) 2019-06-04 2020-06-03 Multispecific proteins

Publications (1)

Publication Number Publication Date
CO2021017845A2 true CO2021017845A2 (es) 2022-01-17

Family

ID=71069894

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0017845A CO2021017845A2 (es) 2019-06-04 2021-12-27 Proteínas multiespecíficas

Country Status (16)

Country Link
US (1) US20200385488A1 (es)
EP (1) EP3980443A1 (es)
JP (1) JP2022535564A (es)
KR (1) KR20220016945A (es)
CN (1) CN114206943A (es)
AR (1) AR119080A1 (es)
AU (1) AU2020289080A1 (es)
BR (1) BR112021024236A2 (es)
CA (1) CA3139051A1 (es)
CO (1) CO2021017845A2 (es)
IL (1) IL288613A (es)
MX (1) MX2021014286A (es)
SG (1) SG11202112921VA (es)
TW (1) TW202112804A (es)
UY (1) UY38739A (es)
WO (1) WO2020245746A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022007122A (es) 2019-12-11 2022-09-09 Molecular Partners Ag Dominios de repetición de anquirina diseñados con residuos de superficie alterados.
CA3176845A1 (en) 2020-05-06 2021-11-11 Patrick AMSTUTZ Novel ankyrin repeat binding proteins and their uses
EP4198050A4 (en) 2020-08-11 2024-05-01 Kanaph Therapeutics Inc FUSION PROTEIN WITH IL-12 AND ANTI-CD20 ANTIBODIES AND USE THEREOF
EP3957649A1 (en) * 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
WO2022190016A1 (en) * 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers
WO2022219185A1 (en) * 2021-04-16 2022-10-20 Athebio Ag N-terminal capping modules of ankyrin repeat domains
WO2023121890A1 (en) * 2021-12-23 2023-06-29 Fbd Biologics Limited Cd47/4-1bb-targeting protein complex and methods of use thereof
WO2024028278A1 (en) 2022-08-01 2024-02-08 Molecular Partners Ag Charge modified designed repeat domains and their use
WO2024037743A1 (en) * 2022-08-16 2024-02-22 Athebio Ag Variants of ankyrin repeat domains
WO2023194628A2 (en) * 2022-08-16 2023-10-12 Athebio Ag Variants of ankyrin repeat domains

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
ATE448301T1 (de) 2000-09-08 2009-11-15 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
WO2010060748A1 (en) 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
CA2776037A1 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd Anti-fibroblast activation protein antibodies and methods and uses thereof
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
SG10201506906VA (en) 2010-09-09 2015-10-29 Pfizer 4-1bb binding molecules
ES2758352T3 (es) 2010-11-26 2020-05-05 Molecular Partners Ag Proteínas de repetición diseñadas que se une a la seroalbúmina
AU2013283296A1 (en) 2012-06-28 2015-02-05 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
EP3004152B1 (en) 2013-05-31 2020-09-30 Molecular Partners AG Designed ankyrin repeat proteins binding to hepatocyte growth factor
WO2016029073A2 (en) 2014-08-22 2016-02-25 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
MY191428A (en) 2014-11-14 2022-06-27 Hoffmann La Roche Antigen binding molecules comprising a tnf family ligand trimer
BR112017020986A2 (pt) * 2015-04-02 2018-08-14 Molecular Partners Ag. proteínas de ligação recombinantes e seu uso
US10717772B2 (en) 2016-09-22 2020-07-21 Molecular Partners Ag Recombinant binding proteins targeting HER2 and serum albumin, and their uses

Also Published As

Publication number Publication date
CA3139051A1 (en) 2020-12-10
MX2021014286A (es) 2022-01-06
AR119080A1 (es) 2021-11-24
EP3980443A1 (en) 2022-04-13
UY38739A (es) 2020-12-31
JP2022535564A (ja) 2022-08-09
CN114206943A (zh) 2022-03-18
TW202112804A (zh) 2021-04-01
KR20220016945A (ko) 2022-02-10
BR112021024236A2 (pt) 2022-04-26
IL288613A (en) 2022-02-01
US20200385488A1 (en) 2020-12-10
AU2020289080A1 (en) 2021-12-23
WO2020245746A1 (en) 2020-12-10
SG11202112921VA (en) 2021-12-30

Similar Documents

Publication Publication Date Title
CO2021017845A2 (es) Proteínas multiespecíficas
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
CL2019002461A1 (es) Arn terapéutico.
ECSP17070706A (es) Inhibidores de bromodominio
CO2021008224A2 (es) Inhibidores de kif18a
CO2018003500A2 (es) Anticuerpos anti-pd-1 y composiciones
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
CR20190071A (es) Compuestos, composiciones y métodos para el tratamiento de enfermedades
CO2022004694A2 (es) Heterociclos bicíclicos como inhibidores de fgfr
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
CL2018001940S1 (es) Automóvil
CL2019003419A1 (es) Polipéptidos que antagonizan la señalización wnt en células tumorales.
ECSP20061378A (es) COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma
CO2022002622A2 (es) Anticuerpos anti-cd73 y composiciones
CL2022001406A1 (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune.
ECSP22010228A (es) Conjugados peptídicos de citotoxinas como terapéuticos
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA202192575A1 (ru) Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
BR112017019176A2 (pt) processos para a preparação de fluorocetolídeos
CL2021001363A1 (es) Métodos de tratamiento de enfermedades con inhibidores de magl.
BR112018068798A2 (pt) composições e métodos para tratamento de doenças parasíticas
DOP2019000220A (es) Arn terapeutico
UY4872S (es) Zapatos
ECSDI18090902S (es) Tobogan clasico